Survey Shows Europe's Perception of Biotechnology to be Favorable - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Survey Shows Europe's Perception of Biotechnology to be Favorable


ePT--the Electronic Newsletter of Pharmaceutical Technology

European confidence and optimism in biotechnology is increasing, according to a survey conducted by the European Commission (EC), with particular support being seen in the area of regenerative medicines, including stem cell research and embryonic stem-cell research.

According to the EC, biotechnology is a major driver in the health and well-being of European citizens, but many factors have affected its development, including consumer safety concerns, strong environmental movements, and little social acceptance. The EC’s Eurobarometer survey, however, showed that 80% of Europeans are in favor of, or unopposed to, biotechnology, although there is still a demand for more facts and communication.

Overall, there was great support for medical biotechnology, with 68% of respondents approving of stem-cell research and 63% approving of embryonic stem-cell research. Additionally, 58% of respondents approve of xenotransplantation, which is subject to moratoria in several countries. The support for medical biotechnology also reaches to nontherapeutic applications, with 56% of respondents approving of research aiming to enhance human performance. However, there was also a strong consensus that strict laws will be needed to alleviate concerns about ethical issues.

Biobanks, facilities that store biological samples, were also well supported. Although only one in three respondents had heard about biobanks, nearly one in two said they would definitely or probably participate in them, with Scandinavian countries showing particular enthusiasm. 

“These findings are very encouraging,” Nathalie Moll, secretary general of the European Association for Bioindustries (EuropaBio), said in a press statement. “They show that Europeans increasingly understand and appreciate the benefits that biotechnology brings... In particular, we are delighted by the overwhelming support for medical biotechnology and for the strong support shown for crop-based and nonfood based biofuels.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here